Tiziana Life Sciences Ltd (TLSA)
NASDAQ: TLSA · Real-Time Price · USD
1.110
-0.040 (-3.48%)
At close: Aug 25, 2026, 4:00 PM EDT
1.130
+0.020 (1.80%)
After-hours: Aug 25, 2026, 7:30 PM EDT
Tiziana Life Sciences Employees
Tiziana Life Sciences had 10 employees as of December 31, 2025. The number of employees increased by 1 or 11.11% compared to the previous year.
Employees
10
Change (1Y)
1
Growth (1Y)
11.11%
Revenue / Employee
n/a
Profits / Employee
-$1,843,100
Market Cap
143.53M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 10 | 1 | 11.11% |
| Dec 31, 2024 | 9 | 0 | - |
| Dec 31, 2023 | 9 | 0 | - |
| Dec 31, 2022 | 9 | -5 | -35.71% |
| Dec 31, 2021 | 14 | 3 | 27.27% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Employee RankingsTLSA News
- 1 day ago - Tiziana Life Sciences Announces Poster Presentation on Phase 2a BANYAN Clinical Trial of Intranasal Foralumab at ALS Nexus 2026 - GlobeNewsWire
- 19 days ago - Tiziana Life Sciences CEO Ivor Elrifi purchases 321,423 shares - TheFly
- 21 days ago - Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer - GlobeNewsWire
- 25 days ago - Tiziana Reports Reduction in Brain Inflammation in Third Multiple System Atrophy Patient Treated with Intranasal Foralumab - GlobeNewsWire
- 4 weeks ago - Tiziana Life Sciences chairman Gabriele Cerrone purchases 42,357 shares at 99c - TheFly
- 4 weeks ago - Tiziana Life Sciences Announces Purchase of Shares by Executive Chairman - GlobeNewsWire
- 2 months ago - Tiziana Life Sciences doses last patient in intranasal foralumab trial - TheFly
- 2 months ago - Tiziana Announces Last Patient Successfully Dosed in its Phase 2 INFORM-MS Trial - GlobeNewsWire